Roivant ditches plan to reacquire Immunovant, putting up $200M investment instead AbbVie plans to move next-gen Aduhelm hopeful for Alzheimer's into the clinic CymaBay secures $100M to bankroll phase 3 development of resurrected liver drug Ipsen puts down $20M in $1B deal with Exicure for rare neuro disorders Moderna looks to Autolus to further fuel its mRNA oncology plans T-knife Therapeutics bags $110M to sharpen solid tumor cell therapy push into the clinic Zentera Therapeutics eyes 2022 Hong Kong listing, but first, a $75M series B to support oncology assets With expanded FDA nod, Regeneron's COVID-19 antibody drug can help the immunocompromised MindMics finds in-ear monitor surpasses ECG in assessing cardiac arrhythmia Pfizer court fight could legalize Medicare copays and unleash 'gold rush' in sales Unleashing immunotherapy against 'cold' prostate tumors with a new protein target Featured Story | By Annalee Armstrong Roivant Sciences was ready to go all-in on bringing former subsidiary Immunovant back under its wing, but now, the parent-to-be is taking a step back and offering up a $200 million strategic investment instead. The complex deal came to light back in May, when Roivant said it planned to reacquire Immunovant, which left the nest and went public via a $100 million special purpose acquisition company, or SPAC, deal in 2019. read more |
| |
|---|
|
Top Stories By Annalee Armstrong The accelerated approval of Biogen’s Aduhelm has caught the eye of AbbVie, which plans to push an Alzheimer’s disease candidate that potentially has a better safety profile into the clinic by year’s end. While reporting second quarter earnings, AbbVie’s R&D chief Mike Severino revealed that AbbVie has identified a beta amyloid candidate that could work faster with reduced risk. read more By Kyle LaHucik A little over a year after resurrecting the liver disease drug seladelpar, CymaBay Therapeutics now has $100 million to bankroll a phase 3 study of the drug. The biopharmaceutical company picked up the non-dilutive financing from Abingworth on Monday to fund trials for seladelpar, including a phase 3 trial and an open-label extension trial. read more By Kyle LaHucik Ipsen is digging deeper into neuroscience, with a $20 million upfront payment to Exicure in a discovery deal for up to two preclinical assets in Huntington's disease and Angelman syndrome. The agreement is back loaded with up to $1 billion in fees and focuses on two rare genetic disorders. read more By Nick Paul Taylor Autolus is among the sea of biotechs seeking to improve on first-generation T-cell therapies but hit bumps in the road, leading it to cut 20% of its staff and seek a partner for one of its candidates earlier this year. But now, it has the validation of a deal with a high-profile partner. Moderna has signed on to leverage Autolus' technology in its mRNA therapies against four immuno-oncology targets. read more By Nick Paul Taylor Investors have flocked to T-knife Therapeutics, which has been taking aim at solid tumors, an area where cell therapies have struggled to perform as well as they have in some blood cancers. Just last year, the biotech raised €66 million ($78 million) and now has reeled in a further $110 million to support a multifront push into clinical trials. read more By Kyle LaHucik Zentera Therapeutics, a joint venture created by Zentalis Pharmaceuticals, raised $75 million in series B funds Monday to advance three assets and add to its oncology-focused pipeline ahead of a likely 2022 public offering in Hong Kong. read more By Kevin Dunleavy The FDA has expanded its EUA for Regeneron's COVID-19 drug as a preventative therapy for those who have been exposed to the disease and who are at high risk to progress to a severe case. read more By Andrea Park They say the surest path to a person’s heart is through their stomach, but according to MindMics, it might actually be through the ears. The startup’s in-ear monitors pick up heartbeats and other measures of cardiac blood flow. read more By Jay Hancock, Kaiser Health News A Pfizer win could cost taxpayers billions of dollars and erase an important control on pharma marketing after decades of regulatory erosion and soaring drug prices, say health policy analysts. read more By Arlene Weintraub University of Michigan researchers found that inhibiting a protein kinase called PIKfyve slowed the growth of prostate tumors in cell lines and mice. It worked even better when they combined it with an immune checkpoint blocker. Now, they're moving an investigational PIKfyve inhibitor that's already been shown to be safe in people into phase 2 trials. read more | | With the expansion of its DNA services, Cobra Biologics, a Charles River company, has capacity to offer rapid 6-week delivery of HQ plasmids as starting material for clinical evaluation of viral vector mediated immunotherapies. 2021 slots available. |
Resources Sponsored By: LabVantage Solutions, Inc. Uncover the real impact of “digital transformation” with practical advice to help you plan your own transformative journey to a harmonized digital ecosystem. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Sponsored by: Evidera, a PDD business Learn about key post-marketing safety study solutions, including registries and REMS, and how they can most effectively help meet regulatory requirements and maximize patient access. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. Diversity, Equity & Inclusion Week August 9-11, 2021 | Virtual Event Medical Affairs Strategic Summit (MASS) September 13-15, 2021 | New Brunswick, NJ Clinical Quality Oversight Forum September 27-29, 2021 | Philadelphia, PA | 